1. Home
  2. SCLXW

as of 07-09-2026 12:03pm EST

$0.20
$0.01
-3.66%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Founded: N/A Country:
United States
United States
Employees: 34 City: PALO ALTO
Market Cap: N/A IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 4.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.78 EPS Growth: N/A
52 Week Low/High: $0.05 - $0.64 Next Earning Date: 03-07-2025
Revenue: $55,152,000 Revenue Growth: 22.02%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -0.27 Index: N/A
Free Cash Flow: 11.4M FCF Growth: N/A

Share on Social Networks: